Global Schizophrenia Therapeutics Market 2017-2021

Publisher Name :
Date: 26-Jul-2017
No. of pages: 81
Price : Single User: US $ 3500  US $ 2500 Corporate User: US $ 5000  US $ 4000
Inquire Before Buying
Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

The analysts forecast global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AstraZeneca

  • Eli Lilly

  • GlaxoSmithKline

  • Johnson & Johnson


Other prominent vendors


  • Alkermes

  • Bristol-Myers Squibb


Market driver


  • Increasing expenditure on prescription drugs

  • For a full, detailed list, view our report


Market challenge


  • Technological advances in non-invasive neuromodulation devices

  • For a full, detailed list, view our report


Market trend


  • Increase in use of LAI antipsychotic drugs

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2021 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Schizophrenia Therapeutics Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
Market outline

PART 05: Schizophrenia: Disease overview
Schizophrenia
Medical intervention for treating schizophrenia
Non-medical interventions for treating schizophrenia

PART 06: Key clinical trials

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation based on drug-class
First-generation antipsychotic drugs
Second-generation antipsychotic drugs
Third generation antipsychotic drugs

PART 09: Geographical segmentation
Market overview based on geography
Schizophrenia therapeutics market in Americas
Schizophrenia therapeutics market in EMEA
Schizophrenia therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
Market drivers
Market challenges

PART 12: Market trends
Rising public interest toward mental health
Increase in use of LAI antipsychotic drugs
Availability of drugs with novel mechanism of action (MoA)

PART 13: Vendor landscape
Competitive landscape

PART 14: Key vendor analysis
AstraZeneca
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Other prominent vendors

PART 15: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Parts of brain affected by schizophrenia
Exhibit 02: Prevalence rate of disease
Exhibit 03: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
Exhibit 04: Types of antipsychotic drugs
Exhibit 05: Use of antipsychotic in schizophrenia
Exhibit 06: Symptoms of disease
Exhibit 07: Non-medical treatment interventions
Exhibit 08: Pipeline landscape based on number of molecules
Exhibit 09: Key clinical trials in global schizophrenia therapeutics market 2016
Exhibit 10: Snapshot of pipeline trends in global schizophrenia therapeutics market
Exhibit 11: Global schizophrenia therapeutics market snapshot
Exhibit 12: Global schizophrenia therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global schizophrenia therapeutics market: Opportunity analysis
Exhibit 14: Five forces analysis
Exhibit 15: Market segmentation of global schizophrenia therapeutics market by drug-class
Exhibit 16: Global schizophrenia therapeutics market segmentation by drug-class
Exhibit 17: Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions)
Exhibit 18: Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 19: Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions)
Exhibit 20: Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions)
Exhibit 21: Global schizophrenia therapeutics market share by geography, 2016 and 2021
Exhibit 22: Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions)
Exhibit 23: Global schizophrenia therapeutics market share by geography, 2016-2021
Exhibit 24: Market scenario in Americas
Exhibit 25: Schizophrenia therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 26: Market scenario in EMEA
Exhibit 27: Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market scenario in APAC
Exhibit 29: Schizophrenia therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 30: Psychotic symptoms
Exhibit 31: Competitive structure analysis of global schizophrenia drugs market 2016
Exhibit 32: AstraZeneca: Strength assessment
Exhibit 33: AstraZeneca: Strategy assessment
Exhibit 34: AstraZeneca: Opportunity assessment
Exhibit 35: AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment

  • Global Depression Drugs Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 10-Aug-2017        Price: US 3480 Onwards        Pages: 119
    Depression is a mental health issue. It's a condition that starts most often in early adulthood. It's also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used f......
  • Global Anti-Depressant Drugs, Devices, And Therapies Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 2500 Onwards        Pages: 145
    Key Findings The Global Anti-depressant drugs, devices, and therapies market is anticipated to grow at a CAGR of 2.12% over the forecast period of 2017- and 2025. The revenue generated by the market is expected to increase from $ 16442 million in 2016 and reach $19712 million by 2025. The anti-depressant drugs, devices, and therapies market is primarily driven because of factors such as a shift in the market from branded to generic drugs, a growing consciousness of depression as a medical......
  • Global Depression Drugs Market 2017 Industry Research Report
    Published: 31-Jul-2017        Price: US 2900 Onwards        Pages: 123
    In the last several years, Global market of Depression Drugs developed rapidly, with an average growth rate of 2.88%. In 2016, Global Revenue of Depression Drugs is nearly 15 B USD. This report studies Depression Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Intellipharmaceutics Pfizer......
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017
    Published: 11-Jul-2017        Price: US 2000 Onwards        Pages: 104
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2017, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. ......
  • Global ADHD Drugs Market Professional Survey Report 2017
    Published: 11-Jul-2017        Price: US 3500 Onwards        Pages: 107
    This report studies ADHD Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Eli Lilly - Janssen Pharmaceuticals, Inc. - Shire - Perdue Pharma ......
  • Global Anxiety and Panic Disorders Drugs Market Research Report 2017
    Published: 11-Jul-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Anxiety and Panic Disorders Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Anxiety and Panic Disorders Drugs in these regions, from 2012 to 2022 (forecast), covering - North America ......
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Cognitive Impairment Associated With Schizophrenia (CIAS) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Cognitive Impairment Associated With Schizophrenia (CIAS). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Cognitive Impairment Associated With Schizophrenia (CIAS). This report provides information on the therapeutic development for Cognitive ......
  • Treatment Resistant Depression - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Treatment Resistant Depression -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Treatment Resistant Depression. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Treatment Resistant Depression. This report provides information on the therapeutic development for Treatment Resistant Depression, dealing with all the pipeline drugs and comparative analysi......
  • Global Risperidone Market Professional Survey Report 2017
    Published: 30-Jun-2017        Price: US 3500 Onwards        Pages: 118
    This report studies Risperidone in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Janssen Pharmaceutica - Teva - Sun Pharmaceutical - Aurobindo - C......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs